Galectin Therapeutics(US:GALT)2025-11-14 12:55Financial Performance - For the quarter ended September 30, 2025, Galectin Therapeutics reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, compared to a net loss of $11.2 million, or ($0.18) per share for the same period in 2024[11]. - Total operating expenses for Q3 2025 were $4.2 million, down from $9.1 million in Q3 2024[15]. - The company reported a total stockholders' deficit of $125.3 million as of September 30, 2025[16]. Research and Development - Research and development expenses for Q3 2025 were $2.6 million, a significant decrease from $7.6 million in Q3 2024, primarily due to the timing of expenditures related to the NAVIGATE clinical trial[9]. - The NAVIGATE trial data presented at the AASLD Annual Meeting showed belapectin's potential to reduce clinically significant portal hypertension (CSPH) from 33.3% to 25.9% (-22.2% change) in the treatment group[5]. - The proportion of patients in the no/low-risk category for CSPH increased from 42.0% to 56.8% (35.2% change) in the belapectin 2 mg/kg group[7]. Financial Position - As of September 30, 2025, the company had $11.5 million in cash and cash equivalents, and a new $10 million line of credit was established to fund operations[9]. - Total liabilities as of September 30, 2025, were $136.4 million, compared to $120.6 million at the end of 2024[16]. Future Outlook - The company anticipates guidance from the FDA regarding the NAVIGATE data package by year-end 2025[9]. - Galectin Therapeutics aims to leverage its expertise and relationships to advance additional development programs in cancer immunotherapy[10].